BioMed Research International / 2019 / Article / Tab 2

Clinical Study

Elevated Preoperative Serum CA125 Predicts Larger Tumor Diameter in Patients with Hepatocellular Carcinoma and Low AFP Levels

Table 2

Comparison of clinicopathological characteristics between two groups stratified by CA125 level (n = 427).

CharacteristicsCA125 ≤30 U/mL (n = 392)CA125 >30 U/mL (n = 35)

Age (years) (≤65/>65)325/6731/40.389
Gender (male/female)340/5226/90.044
Cirrhosis (yes/No)335/5731/40.614
Virus hepatitis (HBV/HCV/non-HBV, non-HCV)332/8/5227/0/80.184
Child-Pugh (A/B)383/932/30.074
ALT (U/L) (≤60/>60)323/6930/50.619
T-Bil (Umol/L) (≤20/>20)304/8826/90.659
Anatomical resection (yes/no)130/26216/190.134
Surgical margin (mm) (≤10/>10)335/5729/60.677
MTD (cm) (≤5/>5)307/8513/22<0.001
Number of nodules (1/>1)332/6031/40.538
Microvascular invasion (yes/no)82/3109/260.507
Differentiation (well/mod, poor)48/3442/330.381
TNM stage

HBV, viral hepatitis B; HCV, viral hepatitis C; ALT, alanine transaminase; T-Bil, total bilirubin; MTD, maximal tumor diameter; IQR, interquartile range. TNM stages were assigned according to the criteria described in the AJCC Cancer Staging Manual (8th Edition).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.